Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ContraFect Corporation.
Public Company Edition: Instil Bio, Connect Biopharma, Finch Therapeutics, Gain Therapeutics and four heath care-focused SPACs launched initial public offerings; Endo raised $1.3bn via note sale; and Rubius Therapeutics, Solid Biosciences and others priced follow-on offerings.
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.
Appointments: Gilead, Shield Therapeutics, Gelesis, TG Therapeutics, Aziyo Biologics, Allogene Therapeutics, Mesoblast and CGT Catapult Make New Hires
Latest appointments announced by pharma and biotech firms.
- Other Names / Subsidiaries
- ContraFect Corp.
- ContraFect Corporation